GlaxoSmithKline plc (ADR) (NYSE:GSK) Performs Quite Well In A Study As Hope Surges About In Becoming The Long-Awited Solution

Top Biotech Stocks

GlaxoSmithKline plc (ADR) (NYSE:GSK), one of the Top Biotech Stocks, has made it public that its phase IIIb study has already carried out an evaluation of the respiratory drug Nucala (mepolizumab)  and it is glad the drug has managed to meet all the primary as well as the secondary endpoints. The MUSCA study showcased that those patients suffering from severe Asthma when put under Nucala attained better lung functioning as well as compared to the ones under standard care or those treated with placebo.

The share price for GlaxoSmithKline has shot up by 8.5% and on the other hand that one of Zacks classified Large Cap Pharmaceuticals industry went up by 7.6%.There were about 551 patients involved in the MUSCA study and all of them were administered 100mg subcutaneous injection. They undertook the same for after every four weeks over a 24 week period.

The results obtained were solely tied to the St. Georges Respiratory Questionnaire (SGRQ) score, which happens to be a patient reported outcome measure and is quite instrumental when it comes to developing an in-depth understanding the severity associated with asthma in terms of the much it does affect a patient’s life-quality. The SQRQ scores indicated that indeed Nucala went a long way towards improving on the quality of life by whole 7.7 units in a close comparison to that of baseline versus placebo over 24 weeks duration.

The study is said to have met the exploratory endpoints in a case where the annual rate of exacerbations  went down by 58%, whereas the that one of  exacerbations demanding for a room visits or hospitalization for that matter went down by 68% for those persons catered for with Nucala co pared to placebo. It was such a great development.

In the US, Nucala has already taken root and it has received approval already as an add-on maintenance treatment for those persons experiencing severe asthma characterized with eosinophilic phenotype. At the moment, it would most probably be in order to point at Nucala as the more effective method considering that it has shown major improvements in markers of asthma control and that moves ahead to cover lung function and the quality of life. Many changes are yet to come forward and we will learn about them on the Biotech Stock News.


Please enter your comment!
Please enter your name here